French bioscience company rebranded.
Facing down past challenges inspires a visionary transformation.
Put yourself in the shoes of a biopharma enterprise that comes achingly close to developing a breakthrough treatment, but falls short at stage three trials. Three times.
Hybrigenics Pharma SA (HYB, Euronext, France) was in just that position. But was there unseen value in the group’s experience, the novel technologies it had developed, and its constituent companies?
If so, how to unlock the potential and unite a new team with a fresh sense of purpose? New CEO Léone Atayi willingly accepted this challenge.
Put yourself in the shoes of a biopharma enterprise that comes achingly close to developing a breakthrough treatment, but falls short at stage three trials. Three times.
Hybrigenics Pharma SA (HYB, Euronext, France) was in just that position. But was there unseen value in the group’s experience, the novel technologies it had developed, and its constituent companies?
If so, how to unlock the potential and unite a new team with a fresh sense of purpose? New CEO Léone Atayi willingly accepted this challenge.